Isomorphic Labs Raises $5B Series C for AI Drug Design
A Clinical Contracts Manager and an Associate Director of Clinical Supply Chain appear on Isomorphic Labs' current hiring list in Cambridge, Massachusetts. Founder and CEO Demis Hassabis leads a company recruiting for the work around experimental medicines as well as the AI that helps design them.
The London-headquartered company announced a $5B Series C on November 17, 2026, co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz and other new investors joined Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The financing supports an enterprise building its own drug-design engine and therapeutic pipeline, including the infrastructure needed as candidates approach clinical development.
For pharmaceutical partners and AI operators, the organizational breadth deserves attention alongside the financing. Isomorphic develops potential medicines through internal and partnered programs. Its latest capital commitment reaches across models, biology and the work of developing the candidates those systems help produce, bringing several very different scientific and operating responsibilities into the same company.
A Completed Series C Follows Two Earlier Financings
Isomorphic's November announcement establishes a completed $5B Series C with named co-leads and participants. The company's accompanying funding release describes continued work on foundational simulation models, therapeutic candidates and global bioengineering capacity. It also identifies translational and clinical-development infrastructure as a use of proceeds, connecting the capital directly to the organization around its medicines.
Thrive Capital led Isomorphic's $2.1B Series B in May 2026, with Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund participating. That followed a $600M first external round in March 2025, also led by Thrive, with GV and Alphabet. The three disclosed rounds add up to $7.7B, including $7.1B across the two announcements this year.
The final Series C valuation was not disclosed in the official announcement. DevCuration's October coverage of Isomorphic's funding talks described an earlier negotiating stage, when the new capital amount and participants were unconfirmed. November's announcement gives the financing a defined size and investor group, while leaving the company's final price outside the disclosed terms. The returning institutions connect this round to the earlier research commitment; Greenoaks and Sequoia now share leadership of the new financing. Those details let readers follow who is committing capital as the scientific and organizational assignment grows.
IsoDDE Connects Molecular Search With Experimental Decisions
The Isomorphic Labs Drug Design Engine, or IsoDDE, combines predictive and generative AI models across molecular-design problems. The company's description spans structures, binding and the properties a molecule needs to be useful. That breadth matters because a promising interaction with a biological target is one part of the design assignment scientists are trying to solve.
In a September explanation of its process, Isomorphic described designers specifying a target, desired selectivity and properties such as solubility and cell permeability. An agent then generates and refines molecular designs computationally. Scientists select compounds to synthesize and test, allowing the experimental work to inform which designs warrant further attention.
One illustrated computational search ran over 2-4 days, according to Isomorphic. That example concerns a portion of preclinical design before the selected molecules are made and tested. Isomorphic presents it as a view into molecular optimization, with synthesis, testing and the candidates' subsequent development still requiring their own work.
The operating opportunity is to make the choice of experiment more informed. A laboratory has to commit people and material to the compounds it tests; a computational engine can change the set of options those people consider. Isomorphic's integrated approach gives researchers developing the models and scientists pursuing the medicines a shared program to improve, making the relationship between those disciplines part of the business.
Internal Medicines and Pharmaceutical Partnerships Share the Engine
Isomorphic's partnership record includes Novartis, Eli Lilly and Johnson & Johnson. The Novartis relationship began in January 2024 around three difficult targets and expanded in February 2025 to include up to three additional research programs. Lilly's collaboration focuses on small molecules against undisclosed targets, while the company describes its broader portfolio as spanning several therapeutic modalities.
These collaborations place Isomorphic's technology inside continuing pharmaceutical research relationships. A partner brings a scientific objective and an organization with its own development decisions. Work on internal candidates gives Isomorphic a different responsibility: organizing its own programs as they advance. The same engine therefore sits within relationships that can require different scientific priorities, coordination and commitments.
The Series C release reports positive preclinical results in internal oncology and immunology programs and partnered work. That is the company's account of progress toward clinical entry. The announcement provides no human-efficacy result, and its description of potential medicines should be read with that development stage in view.
For operators evaluating an AI drug-design business, the combination of internal and partnered work makes organizational execution relevant to the technology discussion. Isomorphic has to keep improving the engine while making it useful to distinct research programs. The resources and people supporting a particular candidate become increasingly consequential as the work moves into another discipline, another team or a partner's development organization.
Clinical Recruitment Makes the Next Operating Assignment Visible
Founder and CEO Demis Hassabis leads Isomorphic alongside President Max Jaderberg, a member of its founding team who helped develop the company's AI approach. Its current leadership roster also includes CSO Miles Congreve, Chief Research Officer Sarah Skerratt and CMO Ben Wolf. The titles place scientific research and clinical development inside the leadership structure around the engine.
Ben Wolf's background includes oncology-development roles at Relay Therapeutics, KSQ Therapeutics and Blueprint Medicines. His clinical responsibility accompanies an organization recruiting in Cambridge, London and Lausanne, where the company's official jobs page identifies its operating locations. A candidate's path through that organization will depend on expertise well beyond the models that helped design it.
The hiring board offers a useful view of that breadth: clinical contracts, clinical supply chain, formulation, toxicology, compute efficiency and inference infrastructure. These listings show recruitment in progress, rather than establishing that any particular trial has begun or allocating a share of the new round to a role. Their coexistence makes the company's intended direction unusually tangible.
Clinical supply and contracts staff will be joining a business that also needs engineers to keep its computational systems working. Isomorphic's candidates move through those connected responsibilities as scientists decide which compounds merit another commitment. The next people taking those jobs will help build the organization around the molecules already occupying the company's research teams.
Healthcare AI funding, last 30 days
DevCuration's funding database tracked 28 Healthcare AI rounds totaling $1.6B in disclosed capital over the past 30 days. Recent deals we covered:
- TestDynamics Secures $9M to Expand Imaging AI EvaluationSeries A · $9M · Nov 17
- Betterness Raises $1M to Expand Miami Wellness NetworksSeed Extension · $1M · Nov 16
- Knit Health Raises $35M Series A for Clinical AI DeploymentSeries A · $35M · Nov 16
- Remedy Robotics Raises $62M Series B for N1 Clinical TrialsSeries B · $62M · Nov 16
- Ellipsis Health Acquires Kouper for AI Care NavigationNov 14
Frequently Asked Questions
How does IsoDDE change which laboratory experiments Isomorphic pursues?
Isomorphic describes using predictive and generative models to refine molecular designs against a target and desired properties. Scientists then select compounds to synthesize and test, connecting computational search to experimental decisions.
Why does clinical-development infrastructure feature in this financing?
The company says the new capital will support translational and clinical-development capacity as its candidates advance toward trials. Its recruitment includes clinical contracts and supply-chain roles, showing some of the operating work being organized around the pipeline.
How do pharmaceutical collaborations fit alongside internal programs?
Isomorphic develops potential medicines internally and through research relationships with Novartis, Eli Lilly and Johnson & Johnson. Partnered work connects the engine to pharmaceutical research priorities, while internal candidates require Isomorphic to organize its own development programs.
How does the Series C relate to Isomorphic’s earlier funding announcements?
The $5B Series C follows a $2.1B Series B announced in May 2026 and a $600M first external round announced in March 2025. These three disclosed rounds add up to $7.7B; that arithmetic is not an exhaustive account of every historical capital contribution.
What does the announcement establish about progress toward patients?
Isomorphic reports positive preclinical findings and describes work toward clinical entry. The financing announcement does not establish human efficacy, disclose a definitive trial-entry date or identify the final Series C valuation.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved